← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Novobiotic Pharmaceuticals, Llc
Cambridge, MA
$52,220,177
Total funding
28
Grants
Funding over time
peak $5.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,660,417 · 25
DOD$8,412,484 · 2
NSF$147,276 · 1
By mechanism
R44$29,290,839 · 9
—$8,559,760 · 3
R43$7,282,002 · 14
R01$7,087,576 · 2
Investigators at Novobiotic Pharmaceuticals, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
LATE-STAGE PRECLINICAL DEVELOPMENT OF TEIXOBACTIN TO TREAT DRUG-RESISTANT INFECTIONS$4,499,475
· FY2025 · Defense Health Agency
DEVELOPMENT OF TEIXOBACTIN TO TREAT DRUG-RESISTANT INFECTIONS$3,913,009
· FY2018 · Department of the Army
Developing Novel Antibiotics Against Yersinia pestis$1,811,326
R44 · FY2007 · AI
Developing Novel Antibiotics Against Yersinia pestis$1,805,783
R44 · FY2008 · AI
Developing Novel Antibiotics Against Yersinia pestis$1,795,670
R44 · FY2006 · AI
Developing Teixobactin for Respiratory Infections$1,469,494
R01 · FY2021 · AI
Developing Teixobactin for Respiratory Infections$1,221,354
R01 · FY2024 · AI
Developing Teixobactin for Respiratory Infections$1,195,129
R01 · FY2022 · AI
Developing Teixobactin for Respiratory Infections$1,147,950
R01 · FY2023 · AI
Developing Teixobactin for Respiratory Infections$1,120,776
R01 · FY2025 · AI
Teixobactin Development for Tuberculosis$999,995
R44 · FY2022 · AI
Preclinical development of Novo29, a new antibiotic$999,992
R44 · FY2019 · AI
Teixobactin Development for Anthrax$999,978
R44 · FY2020 · AI
Isolating novel fungi for antibiotic discovery$999,832
R44 · FY2011 · AI
Drug Discovery from Slow Growing and Rare Microbial Species$999,651
R44 · FY2013 · AI
Isolating novel actinomycetes for antibiotic discovery$999,586
R44 · FY2011 · AI
Preclinical development of teixobactin, a new antibiotic$999,567
R44 · FY2020 · AI
Isolating novel actinomycetes for antibiotic discovery$999,461
R44 · FY2010 · AI
Isolating novel fungi for antibiotic discovery$999,356
R44 · FY2010 · AI
Isolating novel fungi for antibiotic discovery$999,313
R44 · FY2012 · AI